The mOS is 17–20 months after the first observation of metastasis, thus indicating the need to develop novel therapeutic approaches to enhance the survival rates of patients with metastatic BC and failed HER2-targeted therapy [162]. This evidence concerns the gene ERBB2 and breast cancer.